T he word fat has an almost universally negative connotation in modern soci ety, whether as a pejorative term for describing someone who is overweight or as a foodstuff reviled for its deleterious impact on health. Obesity is associated with elevated levels of multiple kinds of fat, and fat accu mulation in tissues is thought to contribute to the development of the unholy trinity of disorders that characterize type 2 diabetes: failure to respond to the glucoseregulating hormone insulin; failure to control glucose production by the liver; and failure of pancre atic βcells, which store and release insulin. Now, however, Yore et al. 1 report in Cell that certain modified fatty acids are found at low, rather than elevated, levels in obese, insulin resistant humans and mice. Furthermore, they show that administering these fatty acids to such mice improves glucose uptake from the blood, enhances insulin secretion and relieves obesityassociated inflammation, suggesting that these naturally occurring fats could be used for diabetes therapy.
Fatty acids and closely related glycerolipid molecules wear multiple biological hats, serv ing as a major energy reservoir, as constituents of cell membranes and as mediators of intracellular signalling. Yore and colleagues' report adds to emerging evidence implica ting specific, lowabundance fatty acids as hormonelike 'lipokine' molecules involved in metabolic regulation.
The same research group had previously shown 2 that elimination of the glucose transport protein GLUT4 from adipose (fat storing) tissue resulted in insulin resistance in liver and muscle -a condition in which cells of these organs have an impaired capac ity to increase glucose uptake in response to insulin, contributing to the abnormally high bloodglucose levels that define diabetes. By contrast, adiposespecific overexpression of GLUT4 caused higher glucose uptake than in control mice -making the mice more sensitive to insulin despite also increasing fat synthesis and levels of circulating fatty acids 3 . The lipidgenerating impact of GLUT4 overexpression was predictable, given that fat cells (adipocytes) use glucose for fat synthe sis. But surprisingly, the enhanced glucose uptake was eliminated by adiposespecific deletion of the transcription factor ChREBP, which regulates fat synthesis, suggesting that the glucoseuptake effect depended on lipo genesis 4 . This finding led Yore and colleagues to the hypothesis that certain fatty acids have positive effects on glucose regulation.
The authors used mass spectrometry to compare the lipid content of the blood serum and adipose tissue taken from these 'diabetes resistant' mice to that of normal mice. They identified five lipids that were significantly elevated in the modified mice, four of which were made up of a typical longchain fatty acid (palmitate, oleate, stearate or palmitoleate) joined by an ester bond to a hydroxylated ver sion of one of the same set of fatty acids. The authors refer to these compounds, which had not been described previously, as fattyacid esters of hydroxyl fatty acids (FAHFAs).
Interestingly, only 6 of the possible 16 FAHFA species were upregulated by GLUT4 overexpression. The most dramatically upreg ulated type of FAHFA in the GLUT4overex pressing mice was palmitic acid hydroxystearic acid (PAHSA), which was then studied further. Yore et al. report that PAHSA (which exists in several isomeric forms depending on the esterification position) can be synthesized by mice provided with the hydroxylated fatty acid precursors, and that it and other FAHFAs are present in mouse serum at low nanomolar concentrations and in laboratorymouse and human food (Fig. 1) . Surprisingly, the levels of FAHFAs are much higher in lowfat, 'standard' mouse diets than in highfat mouse diets used to induce obesity and insulin resistance. These findings suggest that both dietary intake and endogenous synthesis can influence tissue and blood concentrations of FAHFAs.
The authors then studied these fatty acids in two models of insulin resistance in mice: fasting and highfat feeding. Although they found that PAHSA levels fluctuate in response to nutritional state, the direction and magni tude of the changes depended on the PAHSA isoform analysed and the tissue in which altruism of doctors and nurses or the willingness of police officers to enforce punishment might increase when primed with their professional identity.
From a scientific perspective, this study not only supports the economic theory of social identity 2-5 -which considers that gender or occupation, for example, create multiple social identities in individualsbut also links this theory with the economic analysis of lying behaviour 6, 7 . Beyond eco nomics, it shows how behavioural economists can contribute to a broader reflection in sci ence about how people manage their 'multi ple selves' to maintain their selfconcept of honesty 8 . In particular, we should explore further whether professional identity is used strategically by people to reduce their own responsibility for their behaviour and to shift the blame to their companies. Neuroscientific methods could be solicited to understand how and when the human brain lets professional (impersonal) identity become the dominant influence on an individual's moral norms.
It was not Cohn and colleagues' aim to explain how business culture may encourage misbehaviour. However, understanding how the culture of dishonesty evolves is an impor tant issue and it is unlikely that the process is one way. On the one hand, the development of business culture may lead to a 'deindividu ation' process that facilitates the alignment of the individual with the group's prefer ences 9 . If the business culture goes wrong, then individuals may also develop unethical behaviour. On the other hand, individual misconduct may also influence the evolution of business cultures towards more deviant collective norms, through social influence and belief formation. A better understand ing of this dual process will require a theor etical framework that takes into account not only individual motivations but also social interactions and peer effects 10 . ■ 
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DIABETES
The good in fat
A new class of fatty acid -found in food and synthesized by mammalian tissues -enhances glucose uptake from the blood and reduces inflammation, suggesting that these fats might be used to treat diabetes. they were measured, suggesting that PAHSA abundance in various tissues is not clearly cor related with insulin sensitivity in these rodent models. However, in humans, they observed a strong association between PAHSA and insulin sensitivity, and PAHSA levels were significantly lower in insulinresistant than in insulinsensitive individuals.
To test the functional significance of PAHSA in glucose regulation, the authors administered the fatty acid orally to mice before performing a glucosetolerance test, which measures how quickly a dose of glucose is cleared from the blood. They observed reduced basal glucose levels and moreefficient glucose clearance than in mice that had not received PAHSA, and suggested that this effect might be due to improved insulin sensitivity. Although they did not test this idea in mice, they observed a modest potentiation of insulinstimulated glucose uptake in adipocytes in vitro follow ing the addition of PAHSA. However, PAHSA administration to mice also caused increased levels of insulin and glucagonlike peptide1 (a gut hormone that enhances insulin secre tion) in the serum, which might also explain the improved glucose uptake (Fig. 1) . Thus, the mechanism by which PAHSA lowers blood glucose remains to be defined.
FAHFAs are not the only lipids for which therapeutic roles have been suggested in diabetes and related metabolic disorders. For example, administration of a monomeric fatty acid, palmitoleate, which is also produced in adipose tissue during periods of increased fat synthesis, decreases the liver fat content of mice and enhances insulin sensitivity in their skel etal muscles 5 . However, the strong associations between PAHSA and human insulin resistance demonstrated by Yore et al. have not been seen for palmitoleate. Omega3 fatty acids have been suggested to protect against metabolic diseases by stimulation of the Gproteincoupled recep tor GPR120, resulting in reduced inflammation, improved insulin sensitivity and translocation of GLUT4 from the cell interior to the cell surface 6 . Yore et al. demonstrate that PAHSA also decreases the production of the pro inflammatory molecules IL1β and TNFα by macrophage cells, and that both this effect and PAHSAinduced enhancement of glucose uptake and GLUT4 translocation are prevented by inhibiting the activity of GPR120 (Fig. 1) . Thus, it seems that FAHFAs and omega3 fatty acids may converge, at least in part, on the same receptor system to regulate glucose uptake and inflammation. It will be interesting for future studies to compare which is the more potent and efficacious lipid in this regard.
It remains to be determined how the differ ent actions of FAHFAs -sensitizing cells to insulin, stimulating insulin production and reducing inflammation -contribute to glu cose homeostasis. Other questions worthy of future investigation include which enzymes are involved in synthesizing and degrad ing FAHFAs and how they are regulated by changes in diet or, perhaps, by the composi tion of microorganisms in the gut. Finally, and importantly, the effects of FAHFA administra tion on glucose control in humans with type 2 diabetes remains to be explored. Results of these studies will determine whether FAHFAs or their derivatives may indeed become thera peutic agents for metabolic diseases. ■ Deborah M. Muoio 
